HARROW EYE Company Profile
✉ Email this page to a colleague
What is the competitive landscape for HARROW EYE, and when can generic versions of HARROW EYE drugs launch?
HARROW EYE has nineteen approved drugs.
There are thirty US patents protecting HARROW EYE drugs.
There are three hundred and fifty-nine patent family members on HARROW EYE drugs in forty-two countries and twenty-five supplementary protection certificates in ten countries.
Summary for HARROW EYE
| International Patents: | 359 |
| US Patents: | 30 |
| Tradenames: | 18 |
| Ingredients: | 15 |
| NDAs: | 19 |
Drugs and US Patents for HARROW EYE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Harrow Eye | VERKAZIA | cyclosporine | EMULSION;OPHTHALMIC | 214965-001 | Jun 23, 2021 | RX | Yes | Yes | 7,973,081 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Harrow Eye | ILEVRO | nepafenac | SUSPENSION/DROPS;OPHTHALMIC | 203491-001 | Oct 16, 2012 | RX | Yes | Yes | 8,921,337 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Harrow Eye | TOBRASONE | fluorometholone acetate; tobramycin | SUSPENSION/DROPS;OPHTHALMIC | 050628-001 | Jul 21, 1989 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | |||||
| Harrow Eye | IOPIDINE | apraclonidine hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 020258-001 | Jul 30, 1993 | AT | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ||||
| Harrow Eye | MAXIDEX | dexamethasone | SUSPENSION/DROPS;OPHTHALMIC | 013422-001 | Approved Prior to Jan 1, 1982 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | |||||
| Harrow Eye | VERKAZIA | cyclosporine | EMULSION;OPHTHALMIC | 214965-001 | Jun 23, 2021 | RX | Yes | Yes | 8,298,568 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for HARROW EYE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Harrow Eye | MOXEZA | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 022428-001 | Nov 19, 2010 | 4,990,517*PED | ⤷ Subscribe |
| Harrow Eye | VIGAMOX | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 021598-001 | Apr 15, 2003 | 6,716,830*PED | ⤷ Subscribe |
| Harrow Eye | VIGAMOX | moxifloxacin hydrochloride | SOLUTION/DROPS;OPHTHALMIC | 021598-001 | Apr 15, 2003 | 5,607,942*PED | ⤷ Subscribe |
| Harrow Eye | TRIESENCE | triamcinolone acetonide | INJECTABLE;INTRAVITREAL | 022048-001 | Nov 29, 2007 | 6,395,294 | ⤷ Subscribe |
| Harrow Eye | NEVANAC | nepafenac | SUSPENSION/DROPS;OPHTHALMIC | 021862-001 | Aug 19, 2005 | 5,475,034 | ⤷ Subscribe |
| Harrow Eye | TOBRADEX ST | dexamethasone; tobramycin | SUSPENSION/DROPS;OPHTHALMIC | 050818-001 | Feb 13, 2009 | 5,149,694 | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for HARROW EYE drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Ophthalmic | 0.50% | ➤ Subscribe | 2005-12-22 |
| ➤ Subscribe | Ophthalmic Solution | 10.5% | ➤ Subscribe | 2012-02-29 |
| ➤ Subscribe | Ophthalmic Suspension | 0.3% | ➤ Subscribe | 2015-12-21 |
International Patents for HARROW EYE Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Chile | 2020000665 | ⤷ Subscribe |
| Canada | 2659322 | ⤷ Subscribe |
| South Africa | 200509440 | ⤷ Subscribe |
| World Intellectual Property Organization (WIPO) | 2007042262 | ⤷ Subscribe |
| Croatia | P20181337 | ⤷ Subscribe |
| Argentina | 122463 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for HARROW EYE Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0780390 | PA2004012,C0780390 | Lithuania | ⤷ Subscribe | PRODUCT NAME: MOXIFLOXACINI HYDROCHLORIDUM (1-CIKLOPROPIL-6-FLUOR-1,4-DIHIDRO-8-METOKSI-7-((4AS, 7AS)-OKTAHIDRO-6H-PIROLO(3,4-B)PIRIDIN-6-IL)-4-OKSO-3-CHINOLINKARBOKSIRUGSTIES HIDROCHLORIDAS); REGISTRATION NO/DATE: 04/8383/3 20040309 |
| 0999825 | 122013000085 | Germany | ⤷ Subscribe | PRODUCT NAME: NEPAFENAC (OPHTHALMISCHE SUSPENSION); REGISTRATION NO/DATE: EU 1/07/433/002 20130503 |
| 0350733 | 2001C/030 | Belgium | ⤷ Subscribe | PRODUCT NAME: MOXIFLOXACINE CHLORHYDRATE (CORRESPONDANT A MOXIFLOXACINE); NATL. REGISTRATION NO/DATE: 187 IS 328 F 3 20010507; FIRST REGISTRATION: DE 45263.00.00 19990621 |
| 2049079 | PA2017003,C2049079 | Lithuania | ⤷ Subscribe | PRODUCT NAME: CIKLOSPORINAS; REGISTRATION NO/DATE: EU/1/15/990 20170319 |
| 1429780 | SPC/GB12/058 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: A COMBINATION OF CIPROFLOXACIN AND DEXAMETHASONE, PREFERABLY CIPROFLOXACIN HYDROCHLORIDE AND DEXAMETHASONE; REGISTERED: DK DE/11/3337/001/DC 20120808; UK PL000649/0381-0001 20121003 |
| 0350733 | 11/2000 | Austria | ⤷ Subscribe | PRODUCT NAME: MOXIFLOXACIN, DESSEN PHARMAZEUTISCH VERWENDBARE HYDRATE UND SAEUREADDITIONSSALZE, DESSEN ALKALI-ERDALKALI-SILBER- UND GUANIDINIUMSALZE, SOWIE DESSEN C1 - C4 ALKYL- ODER; NAT. REGISTRATION NO/DATE: 1-23494, 1-23495, 1-23496 20000215; FIRST REGISTRATION: DE 45263.00.00 19990621 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
